High Tide Inc. shares rose approximately 21% [1] in pre-market trading after the company reported record revenue for its second fiscal quarter.
The surge reflects growing investor confidence in the cannabis sector following U.S. rescheduling efforts and the company's ability to scale its international operations.
The Canadian operator of Canna Cabana stores reported Q2 fiscal 2026 revenue of $179.3 million [2]. This record figure was accompanied by an adjusted EBITDA of $13.9 million [2].
A significant driver of the growth was the company's expansion into the European market. Its German medical-cannabis subsidiary, Remexian Pharma GmbH, generated $31.6 million [2] in revenue during the period.
High Tide is listed on the NASDAQ exchange and maintains its corporate headquarters in Canada. The company's financial results were released earlier this month, with a corresponding earnings call held on Tuesday, June 26 [4].
Market analysts said the stock's performance is tied to improving sector fundamentals. The combination of record top-line growth and the strategic success of the German subsidiary has positioned the firm as a key player in the evolving global cannabis landscape.
“High Tide Inc. shares rose approximately 21% in pre-market trading”
High Tide's record revenue and the specific success of Remexian Pharma GmbH indicate a strategic shift toward diversification. By establishing a foothold in the German medical market, the company is reducing its reliance on the Canadian retail landscape while benefiting from broader regulatory shifts in the US. The stock's volatility suggests that investors are now pricing in the potential for global scalability rather than just local retail growth.
